Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$31.67 USD

31.67
643,302

-0.14 (-0.44%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AGIO) Outperforming Other Medical Stocks This Year?

Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia

by Zacks Equity Research

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.

Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moving Average Crossover Alert: Agios Pharmaceuticals

by Zacks Equity Research

Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AGIO) Outperforming Other Medical Stocks This Year?

Will Agios Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals

Why Agios (AGIO) Stock Might be a Great Pick

by Zacks Equity Research

Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 30th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios' IND for PKR Activator AG-946 Gets FDA Clearance

by Zacks Equity Research

The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.

Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte's Application for Pemigatinib Gets EMA's Validation

by Zacks Equity Research

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

What Makes Agios Pharmaceuticals (AGIO) a New Buy Stock

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.

Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.

Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially.